Publications

Original papers

  1. Anzenbacherová E, Filipová K, Nobilis M, Anzenbacher P:
    Selective determination of famotidine in human plasma by high performance liquid chromatography in alkaline media with solid phase extraction.
    J. Separ. Sci. 26, 722-726 (2003) (2.018)
  2. Škottová N, Večeřa R, Urbánek K, Váňa P, Walterová D, Cvak L:
    Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets.
    Pharmacol. Res. 47: 17-26, 2003.
  3. Večeřa R, Škottová N, Váňa P, Kazdová L, Chmela Z, Švagera Z, Walterová D, Ulrichová J, Šimánek V:
    Antioxidant Status, Lipoprotein Profile and Liver Lipids in Rats Fed on High-Cholesterol Diet Containing Currant Oil Rich in n-3 and n-6 Polyunsaturated Fatty Acids.
    Physiol. Res. 52: 177-187, 2003.
  4. Švagera Z, Škottová N, Váňa P, Večeřa R, Urbánek K, Belejová M, Kosina P, Šimánek V:
    Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum.
    Phytother. Res.17: 524-530, 2003.
  5. Kousalova L, Anzenbacherova E, Baranova J, et al.:
    Presence of cytochrome P450 enzymes in human CD34(+) haematopoietic progenitor cells Gen.
    Physiol. Biophys. 23, 251-257 (2004) (0.694)
  6. Mičuda S, Mundlová L, Anzenbacherová E, Anzenbacher P, Chládek J, Fuksa L Martínková J:
    Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
    Eur J Clin Pharmacol. 60, 583-589 (2004)(1.972)
  7. Škottová N, Kazdová L, Oliyarnyk O, Večeřa R, Sobolová L, Ulrichová J:
    Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats.
    Pharmacol. Res. 50(2): 123-130, 2004.
  8. Anzenbacherová E, Baranová J, Zuber R, Pěchová A, Anzenbacher P, Souček P, Martínková J:
    Model systems based on experimental animals for studies on drug metabolism in man: Minipig cytochromes P450 CYP3A29 and 2E1.
    Basic Clin. Pharmacol. Toxicol. 96, 244-245 (2005) (1.342)
  9. Baranová J, Anzenbacherova E, Anzenbacher P, Souček P:
    Minipig cytochrome P4502E1: Comparison with human enzyme.
    Drug Metab. Disposition 33, 862-865 (2005) (3.836)
  10. Anzenbacherová E, Hudeček J, Murgida D, Hildebrandt P, Marchal S, Lange R, Anzenbacher P:
    Active sites of two orthologous cytochromes P450 2E1: Differences revealed by spectroscopic methods.
    Biochem. Biophys. Res. Commun. 338, 477-482 (2005) (2.904)
  11. Souček P, Anzenbacher P, Skoumalova I, Dvorak M:
    Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells.
    Stem Cells 23(9), 1417-1422 (2005)
  12. Urbánek K, Kolář M, Čekanová L:
    Utilization of macrolides and the development of Streptococcus pyogenes resistance to erythromycin.
    Pharm World Sci 2005; 27: 104-107. IF 1,009
  13. Urbánek K, Kolář M, Strojil J, Koukalová D, Čekanová L, Hejnar P.:
    Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.
    Pharmacoepidem Dr S 2005; 14(10):741-745. IF 1,773
  14. Zídek Z, Anzenbacher P, Anzenbacherova E, Buchar, Kmoničková E, Potměšil P, Holý A:
    In vivo effects of antiviral acyclic nucleoside phosphonate 9 [2-(phosphonomethoxy)ethyl]adenine (adefovir) on cytochrome P450 system of rat microsomes. J Biomed Sci. Jan 14;1-7 (2006)
  15. Nekvindová J, Mašek V, Veinlichová A, Anzenbacherová E, Anzenbacher P, Zídek Z, Holý A:
    Inhibition of human liver microsomal cytochrome activities by adefovir and tenofovir.
    Xenobiotica, 36(12):1165-77 (2006)
  16. Matal J, Orság J, Nekvindová J, Anzenbacherová E, Veinlichová A, Anzenbacher P, Zídek Z, Holý A:
    Experimental approaches to studies on drug metabolism and drug interaction in man: interaction of acyclic nucleoside phosphonates with human liver cytochromes P450 and flavin-containing monooxygenase 3.
    Neuroendocrinol. Lett. 27, Suppl.2, 27-30 (2006)
  17. Sobolová L, Škottová N, Večeřa R, Urbánek K:
    Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats.
    Pharmacol. Res. 53 (2): 104-112, 2006.
  18. Kolář M, Urbánek K, Vágnerová I, Koukalová D:
    The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci.
    J Clin Pharm Ther 2006; 31(1):67-72. IF 0,966
  19. Hudecek J, Hodek P, Anzenbacherova E, Anzenbacher P:
    Structural analysis of cytochromes P450 shows differences in flexibility of heme 2- and 4-vinyls.
    Biochim Biophys Acta 1770, 413-419 (2007)
  20. Otyepka M, Skopalik J, Anzenbacherova E, Anzenbacher P:
    What common structural features and variations of mammalian P450s are known to date?
    Biochim Biophys Acta 1770, 376-389 (2007)
  21. Lewis D F, Lake B G, Ito Y, Anzenbacher P:
    Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: the importance of lipophilicity for binding and metabolism.
    Drug Metabol Drug Interact. 2006;21(3-4):213-31
  22. Jančová P, Anzenbacherová E, Papoušková B, Lemr K, Lužná P, Veinlichová A, Anzenbacher P, Šimánek V:
    Silybin is metabolized by cytochrome P450 2C8 in vitro.
    Drug Metab Dispos 2007, Nov;35(11):2035-9 IF 4.015
  23. Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P.:
    Azole antimycotics differentially affect rifampicin-induced Pregnane X Receptor (PXR)-mediated CYP3A4 gene expression.
    Drug Metab Dispos. 2007 Nov 12; [Epub ahead of print] 2/2008 IF 3.64
  24. Nekvindová J, Anzenbacher P.:
    Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes.
    Ceska Slov Farm. 2007 Jul;56(4):165-73.
  25. Anzenbacherová E, Anzenbacher P, Zídek Z, Buchar E, Kmoníčková E, Potměšil P, Nekvindová J, Veinlichová A, Holý A:
    In vivo study of the effect of antiviral acyclic nucleotide phosphonate (R) - 9 - [2 -(phosphonomethoxy)propyl]adenine (PMPA, tenofovir) and its prodrug tenofovir disoproxil fumarate on rat microsomal cytochrome P450.
    Physiol Res. 2007 Oct 11; [Epub ahead of print] Printed version 5/2008 IF 2.09
  26. Orolin J, Vecera R, Jung D, Meyer UA, Skottová N, Anzenbacher P.:
    Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha.
    Xenobiotica. 2007 Jul;37(7):725-35. IF 1.613
  27. Vecera R, Klejdus B, Kosina P, Orolin J, Stiborová M, Smrcek S, Vicar J, Dvorák Z, Ulrichová J, Kubán V, Anzenbacher P, Simánek V.:
    Disposition of sanguinarine in the rat.
    Xenobiotica. 2007 May;37(5):549-58. IF 1.613
  28. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P:
    Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.
    Drug Metab Dispos. 2007 Jul; 35(7):1032-41. IF 3.64
  29. Masek V, Machova M, Anzenbacherova E, Brabec V, Anzenbacher V:
    On the possible interaction of platinum chemotherapeutics with human liver microsomal cytochromes P450.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151 (S1) 51-52.
  30. Matal J, Anzenbacherova E, Veinlichova A, Nobilis M, Anzenbacher P:
    Interaction of nabumetone with cytochromes P450 in vitro: comparison of the man and pig.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151 (S1) 53-54.
  31. Večeřa R, Orolin J, Škottová N, Kazdová L, Oliyarnyk O, Ulrichová J, Šimánek V:
    The influence of maca (Lepidium meyenii) on antioxidant status, lipid and glucose metabolism in rat.
    Plant foods hum. nut. 62: 59-63, 2007.
  32. Urbánek K, Kolář M, Lovečková Y, Strojil J:
    Influence of 3rd generation cephalosporin utilization on the of ESBL-positive Klebsiella pneumoniae strains.
    J Clin Pharm Ther 2007;32:403-408. IF 0,966
  33. Vojtová V, Urbánek K:
    Glycylcykliny - nová skupina antibiotik.
    Klin Farmakol Farm 2008; 22(3), p.31-33
  34. Vinklerová I, Urbánek K:
    Polékové akutní pankreatitidy u idiopatických střevních zánětů.
    Klin Farmakol Farm 2008; 22(3), p.18-20
  35. Urbánek K, Kohlová I, Ürge J, Marečková J:
    Informovanost, percepce rizik a compliance pacientů užívajících warfarin.
    Klin Farmakol Farm 2008; 22(1), p.6-10
  36. Vrublova E, Vostalova J, Vecera R, Klejdus B, Stejskal D, Kosina P, Zdarilova A, Svobodova A, Lichnovsky V, Anzenbacher P, Dvorak Z, Vicar J, Simanek V and Ulrichova J:
    The toxicity and pharmacokinetics of dihydrosanguinarine in rat: A pilot study.
    Food and Chemical Toxicology 46 (2008) 2546–2553
  37. Anzenbacherová E, Anzenbacher P, Zídek Z, Buchar E, Kmoníčková E, Potměšil P, Nekvindová J, Veinlichová A, Holý A:
    In Vivo Study of the Effect of Antiviral Acyclic Nucleotide Phosphonate (R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA, tenofovir) and Its Prodrug Tenofovir Disoproxil Fumarate on Rat Microsomal Cytochrome P450.
    Physiol. Res. 57: 761-767, 2008
  38. Kopecný D, Sebela M, Briozzo P, Spíchal L, Houba-Hérin N, Masek V, Joly N, Madzak C, Anzenbacher P, Laloue M.:
    Mechanism-based inhibitors of cytokinin oxidase/dehydrogenase attack FAD cofactor.
    J Mol Biol. 2008 Jul 25;380(5):886-99. Epub 2008 May 24
  39. Matal J, Jancova P, Siller M, Masek V, Anzenbacherova E, Anzenbacher P.:
    Interspecies comparison of the glucuronidation processes in the man, monkey, pig, dog and rat.
    Neuro Endocrinol Lett. 2008 Oct 11;29(5):738-743. [Epub ahead of print]
  40. Skopalik J, Anzenbacher P, and Otyepka M:
    Flexibility of Human Cytochromes P450: Molecular Dynamics Reveals Differences between CYPs 3A4, 2C9, and 2A6, which Correlate with Their Substrate Preferences.
    J. Phys. Chem. B, 2008, 112 (27), 8165-8173
  41. Anzenbacher P, Anzenbacherová E, Lange R, Skopalík J and Otyepka M:
    Active Sites of Cytochromes P450: What are They Like? Acta Chim.
    Slov. 2008, 55, 63–66 63
  42. Večeřa R, Orolin J, Anzenbacher P, Zachařová A:
    Cholesterol and cytochrome P450 4A.
    Prague Medical Report / Vol. 109 (2008) Suppl., p. 121-122
  43. Anzenbacher P, Anzenbacherová E, Otyepka M, Hudeček J:
    Why so many cytochromes P450?
    Prague Medical Report / Vol. 109 (2008) Suppl., p. 5
  44. Večeřa R, Anzenbacher P, Orolin J, Škottová N:
    Effects of silymarin and fenofibrate on selected cytochromes P450.
    Sborník ISBN: 978-80-254-2834-4

Reviews

  1. Anzenbacher P., Anzenbacherová E.:
    Cytochromes P450 and metabolism of xenobiotics.
    CMLS, Cell. Mol. Life Sci. 58, 737-747 ( 2001) (4,54)
  2. Anzenbacher P.:
    Úvod do farmakogenetiky.
    Klin. farmakol. a farmacie 16 (1-2), 7-9 (2002)
  3. Zuber R., Anzenbacherová E., Anzenbacher P.:
    Cytochromes P450 and experimental models of drug metabolism.
    J. Cell. Mol. Med. 6 (2), 189-198 (2002)
  4. Anzenbacher P., Anzenbacherová E.:
    Cytochromes P450: Review of their basic principles.
    Proc. Indian Natl. Science Acad. B 69 2003
  5. Anzenbacher P., Anzenbacherová E.: Cytochromes P450:
    How to study their structure and function and which animal model to choose.
    Nova Acta Leopoldina NF 87: 11-20 (2003)